RELATING TO HEALTH AND SAFETY -- PRESCRIPTION DRUG SAVINGS AND, TRANSPARENCY ACT OF 2026
Impact
The bill is expected to yield substantial benefits, including reduced administrative costs, increased manufacturer rebates returned to Medicaid, and improved access to necessary medications for beneficiaries. The proposed study will assess various management structures, including the current model, which predominantly uses multiple pharmacy benefit managers, as well as alternatives like a single-state preferred drug list or a fee-for-service approach. This could lead to significant changes in how Medicaid prescription drugs are administered, affecting budget allocations and operational efficiencies.
Summary
House Bill 8172, also known as the Prescription Drug Savings and Transparency Act of 2026, aims to enhance the management of prescription drug benefits within the Rhode Island Medicaid program. The legislation is driven by the recognition that prescription drug costs constitute a significant and escalating burden on the state budget, affecting vulnerable populations such as children, seniors, and low-income families. The bill mandates a comprehensive study by the office of the auditor general to evaluate the potential benefits of consolidating prescription drug management, drawing on successful approaches adopted by other states like Kentucky and Connecticut.
Contention
While the bill is positioned as a necessary reform aimed at increasing efficiency and transparency, it may face contention regarding the implications for current contractual relationships with pharmacy benefit managers. Concerns may arise about the extent of oversight and access required by the auditor general to enforce the guidelines and whether this could interfere with established operational practices. Furthermore, as the bill seeks to unify the drug management system under a consolidated approach, local entities may raise questions about potential disruptions to existing services and their ability to meet specific community needs.
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provide the list to the attorney general to obtain reasons for the cost increases.
To Regulate Pharmacy Benefits Managers; To Amend The Law Concerning The State And Public School Life And Health Insurance Program; And To Amend The Law Concerning Certain Health Benefit Plans.